COVID-19NCT05835102
Influence of Nutritional Indices on the Prognosis of Patients With SARS-CoV-2 Infection
An observational study of COVID-19, run by Juan Kang at 1 site in China.
Trial summary
With the decline of virulence after the mutation of the SARS-CoV-2 , based on the national life and health and national development needs, the domestic SARS-CoV-2 infection epidemic prevention policy has changed, and the number of people infected by the SARS-CoV-2 has increased. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- COVID-19
- How many people
- 800 participants
- Where
- 1 siteChina
- Study dates
- 1 May 2023to 9 Dec 2025
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with a positive SARS-CoV-2 nucleic acid test or a positive SARS-CoV-2 antigen test.
Who may be able to join
- Patients with a positive SARS-CoV-2 nucleic acid test or a positive SARS-CoV-2 antigen test.
Who cannot join
- People with end-stage malignant tumors;
- Nutritional intake disorders, mainly dependent on enteral and parenteral nutrition supporters;
- paralyzed;
- Intravenous drug addicts.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, 400000
Juan Kang, M.D., +8613996112052, 68368892@qq.com
About this study
Official title: Study on the Influence of Nutritional Indices on the Prognosis of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection
With the decline of virulence after the mutation of the SARS-CoV-2 , based on the national life and health and national development needs, the domestic SARS-CoV-2 infection epidemic prevention policy has changed, and the number of people infected by the SARS-CoV-2 has increased. Nutritional status is an indicator of human health and plays an important role in fighting disease. Malnutrition has been found to correlate with prognosis in patients infected with the SARS-CoV-2 infection . Timely identification and assessment of the patient's nutritional status and early implementation of relevant nutritional intervention are conducive to the recovery of the patient's condition.
In clinical practice, it is necessary to improve nutrition as an aspect of the comprehensive diagnosis and treatment of patients with SARS-CoV-2 infection, but there is still a lack of relevant nutritional indicators or models to simply and accurately assess the nutritional status of patients.The purpose of this study was to evaluate the effects of PNI, NRI, GNRI, albumin level, vitamin D, chest muscle area and density on the clinical characteristics and prognosis of patients with SARS-CoV-2 infection, to find the nutritional predictors of severe disease in patients with SARS-CoV-2 infection, and to establish a simpler and more accurate nutritional evaluation model. To provide evidence for targeted nutritional interventions in patients with SARS-CoV-2 infection.
Read the detailed description
Patients with SARS-CoV-2 infection attending the Second Affiliated Hospital of Chongqing Medical University were included in the retrospective study. Participants met the inclusion and exclusion criteria. Data to be collected include age, sex, height, and weight at initial treatment; Blood routine, liver function, kidney function, coagulation function, electrolytes, vitamin D, C-reactive protein, ferritin; CT and MRI information; Underlying diseases, complications, treatment options, etc. Follow up patients until discharge or death. After the data collection, statistical methods such as chi-square test and logistic regression analysis were used to evaluate the impact of nutritional factors on the prognosis of patients infected with SARS-CoV-2 infection.
- Conditions
- COVID-19
- Keywords
- prognostic nutritional index, geriatric nutritional risk index, pectoralis muscle index, prognosis
- Medical subject headings
- COVID-19
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Patients With SARS-CoV-2 Infection | Patients who test positive for SARS-CoV-2 nucleic acid or SARS-CoV-2 antigen |
What is being measured
The primary outcome is the main question the study is designed to answer.
Death
Death due to Respiratory failure or other diseases
Measured: October 2022 to January 2023
cure
the patients with SARS-CoV-2 infection are cured and discharged from hospital
Measured: October 2022 to January 2023
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Apr 2023
- Study start1 May 2023
- Primary completion7 Dec 2025 (estimated)
- Study completion9 Dec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for COVID-19Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 800 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Juan Kang
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Juan Kang, The Second Affiliated Hospital of Chongqing Medical University
- Investigators
- Juan Kang, M.D., Study chair, The Second Affiliated Hospital of Chongqing Medical University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05835102
- Sponsor's protocol ID
- 2023-19
- Status last verified
- Jun 2025
- First submitted
- 23 Apr 2023
- Last updated
- 25 Jun 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study on the Influence of Nutritional Indices on the Prognosis of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection
- ClinicalTrials.gov ID
- NCT05835102
- Acronym / sponsor ID
- 2023-19
- Conditions
- COVID-19
- Keywords
- prognostic nutritional index, geriatric nutritional risk index, pectoralis muscle index, prognosis
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 800 participants (estimated)
- Lead sponsor
- Juan KangUniversity, hospital or other
- Study start
- 1 May 2023 (actual)
- Primary completion
- 7 Dec 2025 (estimated)
- Study completion
- 9 Dec 2025 (estimated)
- First posted
- 28 Apr 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
With the decline of virulence after the mutation of the SARS-CoV-2 , based on the national life and health and national development needs, the domestic SARS-CoV-2 infection epidemic prevention policy has changed, and the number of people infected by the SARS-CoV-2 has increased. Nutritional status is an indicator of human health and plays an important role in fighting disease. Malnutrition has been found to correlate with prognosis in patients infected with the SARS-CoV-2 infection . Timely identification and assessment of the patient's nutritional status and early implementation of relevant nutritional intervention are conducive to the recovery of the patient's condition.
In clinical practice, it is necessary to improve nutrition as an aspect of the comprehensive diagnosis and treatment of patients with SARS-CoV-2 infection, but there is still a lack of relevant nutritional indicators or models to simply and accurately assess the nutritional status of patients.The purpose of this study was to evaluate the effects of PNI, NRI, GNRI, albumin level, vitamin D, chest muscle area and density on the clinical characteristics and prognosis of patients with SARS-CoV-2 infection, to find the nutritional predictors of severe disease in patients with SARS-CoV-2 infection, and to establish a simpler and more accurate nutritional evaluation model. To provide evidence for targeted nutritional interventions in patients with SARS-CoV-2 infection.
Detailed description
Patients with SARS-CoV-2 infection attending the Second Affiliated Hospital of Chongqing Medical University were included in the retrospective study. Participants met the inclusion and exclusion criteria. Data to be collected include age, sex, height, and weight at initial treatment; Blood routine, liver function, kidney function, coagulation function, electrolytes, vitamin D, C-reactive protein, ferritin; CT and MRI information; Underlying diseases, complications, treatment options, etc. Follow up patients until discharge or death. After the data collection, statistical methods such as chi-square test and logistic regression analysis were used to evaluate the impact of nutritional factors on the prognosis of patients infected with SARS-CoV-2 infection.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients With SARS-CoV-2 Infection | – | –Patients who test positive for SARS-CoV-2 nucleic acid or SARS-CoV-2 antigen |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with a positive SARS-CoV-2 nucleic acid test or a positive SARS-CoV-2 antigen test.
Key inclusion criteria (1 listed)
- Patients with a positive SARS-CoV-2 nucleic acid test or a positive SARS-CoV-2 antigen test.
Key exclusion criteria (4 listed)
- People with end-stage malignant tumors;
- Nutritional intake disorders, mainly dependent on enteral and parenteral nutrition supporters;
- paralyzed;
- Intravenous drug addicts.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Death
Time frame: October 2022 to January 2023
Death due to Respiratory failure or other diseases
cure
Time frame: October 2022 to January 2023
the patients with SARS-CoV-2 infection are cured and discharged from hospital
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Jun 2025.
- Individual participant dataSharing planned: No
Related trials for COVID-19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Juan Kang, M.D. study chair
The Second Affiliated Hospital of Chongqing Medical University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of COVID-19, run by Juan Kang at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 25 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Juan Kang, M.D. (8613996112052, 68368892@qq.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Death (time frame: October 2022 to January 2023). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Jun 2025.